RxDoctor Payments Data

Dewey Pillai, MD

Family Medicine · Santa Clarita, CANPI 1134161482

Payments from drug & device makers

$684in general payments, 2019–2025

Across 29 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$294
  • Dexcom, Inc.$140
  • Abbott$85
  • Otsuka America Pharmaceutical, Inc.$83
  • Boston Scientific$25
  • GSK$22
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$684 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$25,488
Medicare patients
79
Services billed
273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$73,296
JardianceEmpagliflozin23$30,202
JanuviaSitagliptin Phosphate24$29,859
TrulicityDulaglutide21$29,703
MounjaroTirzepatide23$23,934
EliquisApixaban21$23,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,154
Breo ElliptaFluticasone/Vilanterol16$8,244
Albuterol Sulfate HfaAlbuterol Sulfate152$5,405
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,207
Atorvastatin Calcium315$3,144
Gabapentin135$2,410
Econazole Nitrate13$2,373
Rosuvastatin Calcium109$2,225
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$2,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$294$53,63744 claims
GSKTrelegy Ellipta, Breo Ellipta$22$24,39835 claims
PfizerEliquis$18$23,53421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Santa Clarita

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →